Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...

Claiming Science magazine's breakthrough of the year in 2023 , these drugs are an absolute revelation: they give you long-lasting weight loss as long as you continue taking them .

Insufficient light exposure in childhood may disrupt blood sugar control, leading to insulin resistance and metabolic issues, ...

In 2024, a plethora of novel therapeutic strategies for kidney disease progressed to clinical trials, including an RNA interference therapeutic, a glucagon ... roles in cell biology and physiology.

The Big Pharma already has efinopegdutide, a dual GLP-1/glucagon receptor co-agonist ... we aim to build on our experience targeting incretin biology to evaluate HS-10535 and its potential to ...

The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

From indestructible tardigrades to body-merging comb jellies, animals can teach humans so much about medicine, robotics, ...

Retatrutide, a synthetic peptide with unique properties, has recently gained attention for its multifunctional roles and the ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Consider the parallels. Like rimonabant before it, wegovy (called a "GLP-1 agonist" due to its ability to simulate the effects of a naturally occurring appetite hormone in the human body called ...